Loading patent…
AssigneeMedImmune, LLC
InventorsRichard Woessner, Peter Kiener, Melissa Dormitzer, William Walsh, Jon Heinrichs
Estimating the term…
The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more antagonists of Integrin αVβ3 alone or in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more antagonists of Integrin αVβ3 and/or one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of a therapeutically or prophylactically effective amount of one or more antagonists of Integrin αVβ3 alone or in combination with standard and experimental therapies for treatment or prevention of cancer. Also included are methods for screening for epitope-specific Integrin αVβ3 antagonists which can be used according to the methods of the invention. In addition, methods for facilitating the use of Integrin αVβ3 antagonists in the analysis of Integrin αVβ3 expression in biopsies of animal model and clinical study samples are also contemplated.
A method of preventing, treating or managing cancer in a patient in need thereof, said method comprising administering to said patient a dose of an effective amount of VITAXIN® or an antigen-binding fragment thereof, or an antibody or fragment thereof that competes with VITAXIN® for binding to Integrin αVβ3 and a dose of an effective amount of one or more other cancer therapies.
A method of preventing, treating or managing cancer in a patient in need thereof, said method comprising administering to said patient a dose of an effective amount of VITAXIN® or an antigen-binding fragment thereof, or an antibody or fragment thereof that competes with VITAXIN® for binding to Integrin αVβ3 conjugated to a therapeutic moiety.
A pharmaceutical composition comprising a therapeutically effective amount of Vitaxin® or an antigen-binding fragment thereof or an antibody or fragment thereof that competes with VITAXIN® for binding to Integrin αVβ3 and a therapeutically effective amount of one or more anti-cancer agents;
A method of screening for antibodies with specific binding affinity for the epitope specifically recognized by Vitaxin® comprising identification of monoclonal antibodies that bind to wild type human Integrin αVβ3 but not to human Integrin αVβ3 with residues 171, 173 and 174 substituted with amino acids Gln, Ile and Lys, respectively in the human β3.chain.
A method for detecting Integrin αVβ3 in tissue comprising fixing said tissue in 70% EtOH for 24 hours prior to paraffin embedding, wherein said tissue is not frozen, and staining with antibody LM609 for immunohistodetection of Integrin αVβ3.
Dependencies are inferred from the claim text.